Table 1.
Baseline Characteristics
| Characteristic | Placebo (n = 561) |
mAb-Treated (n = 1554) |
Total (N = 2115) |
|---|---|---|---|
| Study treatment/placebo | |||
| Amubarvimab + romlusevimab | 0 (0) | 405 (26) | 405 (19) |
| Bamlanivimab 7000 mg | 0 (0) | 48 (3) | 48 (2) |
| Bamlanivimab 700 mg | 0 (0) | 111 (7) | 111 (5) |
| Bamlanivimab 700 mg (uncontrolled cohort) | 0 (0) | 990 (64) | 990 (47) |
| Placebo for amubarvimab + romlusevimab | 403 (72) | 0 (0) | 403 (19) |
| Placebo for bamlanivimab 7000 mg | 46 (8) | 0 (0) | 46 (2) |
| Placebo for bamlanivimab 700 mg | 112 (20) | 0 (0) | 112 (5) |
| Age, y | |||
| Median (Q1, Q3) | 49 (38, 57) | 50 (39, 60) | 49 (39, 59) |
| ≥60 | 118 (21) | 408 (26) | 526 (25) |
| Sex, female | 287 (51) | 797 (51) | 1084 (51) |
| Gender identity, cisgender | 559 (>99) | 1546 (99) | 2105 (>99) |
| Racea | |||
| White | 430 (77) | 1263 (81) | 1693 (80) |
| Black/African American | 74 (13) | 159 (10) | 233 (11) |
| Asian | 30 (5) | 75 (5) | 105 (5) |
| Ethnicitya | |||
| Hispanic/Latino | 249 (45) | 564 (36) | 813 (39) |
| Country | |||
| Argentina | 49 (9) | 49 (3) | 98 (5) |
| Brazil | 18 (3) | 15 (1) | 33 (2) |
| Mexico | 2 (<1) | 3 (<1) | 5 (<1) |
| Philippines | 1 (<1) | 0 (0) | 1 (<1) |
| South Africa | 59 (11) | 72 (5) | 131 (6) |
| United States | 432 (77) | 1415 (91) | 1847 (87) |
| History of SARS-CoV-2 vaccination (yes) | 39 (7) | 32 (2) | 71 (3) |
| Higher risk of severe COVID-19 progressionb (yes) | 477 (85) | 1112 (72) | 1589 (75) |
| Comorbidities | |||
| Hypertensiona | 200 (36) | 529 (34) | 729 (35) |
| Obesitya | 137 (24) | 290 (19) | 427 (20) |
| Diabetesa | 78 (14) | 214 (14) | 292 (14) |
| Days from symptom onset to study day 0 | |||
| Median (Q1, Q3) | 6 (4, 7) | 5 (4, 7) | 6 (4, 7) |
| ≤5 | 259 (46) | 790 (51) | 1049 (50) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: COVID-19, coronavirus disease 2019; mAb, monoclonal antibody; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Data were missing for the following variables: race (n = 2), ethnicity (n = 5), hypertension (n = 3), obesity (n = 3), diabetes (n = 3).
“Higher” risk is based on the protocol definition at time of enrollment as defined in Supplementary Table 1.